Argen X SE - ADR
ARGX
Get informed when a big investor buys or sells
+ FollowEarnings Call Q4 2025
February 26, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
55% downsideOvervalued by 55% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $57.10 Billion |
|---|---|
| Enterprise Value | $53.61 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $21.14 |
| Beta | -0.02 |
| Outstanding Shares | 62,185,445 |
Return
| Return on Equity | 25.29% |
|---|---|
| Return on Assets | 21.22% |
| Return on Invested Capital | 25.00% |
Valuation & Multiples
| P/E Ratio | 33.17 |
|---|---|
| PEG | 13.71 |
| Price to Sales | 10.09 |
| Price to Book Ratio | 6.8 |
| Enterprise Value to Revenue | 9.47 |
| Enterprise Value to EBIT | 25.36 |
| Enterprise Value to Net Income | 25 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 48.11% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.28%▼ 46.64% |
|---|---|
| Total Invested | $157.53M▼ 99.25% |
| Investors Holding | 65▼ 431.00% |
ESG Score
No data
About Argen X SE
CEO: Tim Van Hauwermeiren Relevant Senate Committees
Controls Medicare and Medicaid policy; decisions on reimbursement rates and drug price negotiations are critical to the commercial success of biological products.
Directly sets the funding for the FDA and NIH, impacting the speed of regulatory reviews and the availability of federal research grants.
Primary oversight of the FDA and NIH; members have direct influence and non-public knowledge regarding drug approval processes and clinical trial regulations.
Oversees intellectual property and patent law, which are the fundamental drivers of valuation and market exclusivity for biological products.
This committee frequently investigates drug pricing and the accessibility of treatments for chronic conditions, creating significant headline and regulatory risk for biologics.